⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FBIO News
Fortress Biotech, Inc.
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
globenewswire.com
FBIO
DERM
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics
globenewswire.com
NVS
CGNX
FBIO
CTXR
Form 8-K
sec.gov
FBIO
FBIOP
AXSM
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
FBIO
FBIOP
Form 8-K
sec.gov
FBIOP
FBIO
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
DERM
FBIO
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
globenewswire.com
FBIO
DERM
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Form 8-K
sec.gov
FBIOP
FBIO